Physician profile
Hector D Ceccoli
NPI 1548250392
$13,240.04
in general payments reported to CMS, 2019-2025
38 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,755 · 2020: $759 · 2021: $1,660 · 2022: $1,661 · 2023: $2,580 · 2024: $3,794 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,178 · Travel and Lodging: $1,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,178.07 |
| Travel and Lodging | $1,227.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $1,792.44 | 2022-2025 | Barostim Neo System |
| Abbott Laboratories | $1,584.31 | 2019-2025 | Mitraclip, Cardiomems, Aveir |
| Novartis Pharmaceuticals Corporation | $1,090.22 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $1,082.37 | 2023-2024 | Optimizer, Optimizer |
| Janssen Pharmaceuticals, INC | $805.09 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $656.49 | 2019 | |
| Pfizer INC. | $628.13 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $611.46 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $488.74 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $437.71 | 2019-2025 | Jardiance |
| Amgen INC. | $437.54 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $397.11 | 2019-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $376.78 | 2021-2025 | Amvuttra, Onpattro |
| Novo Nordisk INC | $339.40 | 2021-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $323.16 | 2021-2023 | Verquvo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $305.11 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $213.80 | 2022-2025 | |
| Abiomed | $204.21 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $198.23 | 2019-2024 | |
| Medtronic, INC. | $169.67 | 2022-2024 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Heartflow, INC. | $168.87 | 2023-2024 | Ffrct |
| Lundbeck LLC | $145.20 | 2019 | |
| Amarin Pharma, INC. | $126.16 | 2020 | |
| Atricure, INC. | $112.02 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $92.79 | 2019 | |
| Cardiovascular Systems INC. | $69.24 | 2022-2023 | Diamondback Coronary |
| Gilead Sciences, INC. | $64.97 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $62.13 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $57.93 | 2019-2024 | Watchman Flx |
| Terumo Medical Corporation | $44.61 | 2023 | Tr Band, Glidesheath Slender |
| Irhythm Technologies, INC. | $38.36 | 2024 | Zio Monitor, Zio Xt Patch |
| Kiniksa Pharmaceuticals International, Plc | $30.52 | 2024 | Arcalyst |
| Siemens Medical Solutions USA, INC. | $27.70 | 2023-2024 | Artis Icono Biplane, Artis Icono Floor |
| Cmp Pharma, INC. | $27.32 | 2021-2022 | |
| Philips North America LLC | $15.86 | 2023 | |
| Biotronik INC. | $14.39 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Ceccoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.